肝内胆管癌系统治疗与局部治疗的现状及进展
Current Status and Progress of Systemic and Local Therapy for Intrahepatic Cholangiocarcinoma
摘要: 肝内胆管癌是原发性肝癌的一种,发病率仅次于原发性肝细胞癌,其恶性程度高、预后差、早期临床症状不典型,多数患者确诊时已失去手术机会。对于中晚期肝内胆管癌的治疗通常以化疗为主,局部治疗手段有肝动脉化疗栓塞、放疗、射频消融治疗等。近年来,靶向及免疫治疗在各种实体肿瘤的应用愈加广泛,且取得了令人鼓舞的成绩。因此,随着各种治疗手段的不断进展,联合治疗似乎成为一种可行的治疗策略。本文就肝内胆管癌的系统治疗与局部治疗的现状及进展作如下综述。
Abstract: Intrahepatic cholangiocarcinoma is a type of primary liver cancer, with an incidence rate second only to primary hepatocellular carcinoma. It has a high degree of malignancy, poor prognosis, and atypical early clinical symptoms. Most patients have lost the opportunity for surgery when diag-nosed. The treatment for intermediate and advanced intrahepatic cholangiocarcinoma is usually chemotherapy, and local treatment methods include hepatic arterial chemoembolization, radio-therapy, radiofrequency ablation, etc. In recent years, targeted and immunotherapy have been in-creasingly used in various solid tumors and have achieved encouraging results. Therefore, as var-ious treatments continue to advance, combination therapy appears to be a feasible treatment strat-egy. This article reviews the current status and progress of systemic treatment and local treatment of intrahepatic cholangiocarcinoma as follows.
文章引用:刘永林, 金成兵. 肝内胆管癌系统治疗与局部治疗的现状及进展[J]. 临床医学进展, 2024, 14(3): 131-141. https://doi.org/10.12677/ACM.2024.143676

参考文献

[1] Kelley, R.K., Bridgewater, J., Gores, G.J. and Zhu, A.X. (2020) Systemic Therapies for Intrahepatic Cholangiocarcinoma. Journal of Hepatology, 72, 353-363. [Google Scholar] [CrossRef] [PubMed]
[2] Esnaola, N.F., Meyer, J.E., Karachristos, A., et al. (2016) Evaluation and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. Cancer, 122, 1349-1369. [Google Scholar] [CrossRef] [PubMed]
[3] Lamarca, A., Edeline, J., McNamara, M.G., et al. (2020) Current Standards and Future Perspectives in Adjuvant Treatment for Biliary Tract Cancers. Cancer Treatment Reviews, 84, Article ID: 101936. [Google Scholar] [CrossRef] [PubMed]
[4] Mosconi, C., Solaini, L., Vara, G., et al. (2021) Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma—A Systemic Review and Meta-Analysis. CardioVascular and Interventional Radiology, 44, 728-738. [Google Scholar] [CrossRef] [PubMed]
[5] Judith, W, Grace, C.-R., Megan, D., et al. (2023) Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study. JVIR, 30, 1185-1192. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, J., Wang, J., Zhou, H., et al. (2018) Efficacy and Safety of Endoscopic Radiofrequency Ablation for Unresectable Extrahepatic Cholangiocarcinoma: A Randomized Trial. Endoscopy, 50, 751-760. [Google Scholar] [CrossRef] [PubMed]
[7] Oh, D.Y., He, A.R., Qin, S., et al. (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence 1, EVIDoa2200015. [Google Scholar] [CrossRef
[8] Yang, J., Zhu, F., Wang, H., Rong, L., Wu, P., Li, Z., et al. (2022) The Efficacy and Safety of Immune Checkpoint Inhibitor Based Combination Therapy in Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Cancer Manag Res, 14, 1399-1411.
[9] Mazzaferro, V., Gorgen, A., Roayaie, S., Droz Dit Busset, M. and Sapisochin, G. (2020) Liver Resection and Transplantation for Intrahepatic Cholangiocarcinoma. Journal of Hepatology, 72, 364-377. [Google Scholar] [CrossRef] [PubMed]
[10] Chun, Y.S. and Javle, M. (2017) Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control, 24, 1-7. [Google Scholar] [CrossRef] [PubMed]
[11] Amin, M.B., Greene, F.L., Edge, S.B., et al. (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population-Based to a More “Personalized” Approach to Cancer Staging. CA: A Cancer Journal for Clinicians, 67, 93-99. [Google Scholar] [CrossRef] [PubMed]
[12] Wright, G.P., Perkins, S., Jones, H., et al. (2018) Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies. Annals of Surgical Oncology, 25, 83-90. [Google Scholar] [CrossRef] [PubMed]
[13] Primrose, J.N., Fox, R.P., Palmer, D.H., et al. (2019) Capecitabine Compared with Observation in Resected Biliary Tract Cancer (BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study. The Lancet Oncology, 20, 663-673.
[14] Kupietzky, A. and Ariche, A. (2022) Surgical Aspects of Intrahepatic Cholangiocarcinoma. Cancers, 14, Article No. 6265. [Google Scholar] [CrossRef] [PubMed]
[15] 潘奇, 王鲁. 肝内胆管细胞癌手术难点和范围[J]. 中国实用外科杂志, 2016, 36(6): 706-708.
[16] Farges, O., Fuks, D., Boleslawski, E., et al. (2011) Influence of Surgical Margins on Outcome in Patients with Intrahepatic Cholangiocarcinoma: A Multicenter Study by the AFC-IHCC-2009 Study Group. Annals of Surgery, 254, 824-830. [Google Scholar] [CrossRef
[17] Shimada, K., Sano, T., Nara, S., et al. (2009) Therapeutic Value of Lymph Node Dissection during Hepatectomy in Patients with Intrahepatic Cholangiocellular Carcinoma with Negative Lymph Node Involvement. Surgery, 145, 411-416. [Google Scholar] [CrossRef] [PubMed]
[18] Eliza, W.B., Jordan, M.C., Timothy, M.P., et al. (2021) Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. Journal of Clinical Medicine, 10, Article No. 104. [Google Scholar] [CrossRef] [PubMed]
[19] Edeline, J., Benabdelghani, M., Bertaut, A., et al. (2019) Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. Journal of Clinical Oncology, 37, 658-667. [Google Scholar] [CrossRef
[20] Hong, J.C., Jones, C.M., Duffy, J.P., et al. (2011) Comparative Analysis of Resection and Liver Transplantation for Intrahepatic and Hilar Cholangiocarcinoma: A 24-Year Experience in a Single Center. Archives of Surgery, 146, 683-689. [Google Scholar] [CrossRef] [PubMed]
[21] Primrose, J.N., Fox, R.P., Palmer, D.H., et al. (2019) Capecitabine Compared with Observation in Resected Biliary Tract Cancer (BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study [Published Correction Appears in Lancet Oncol. 2019 Apr 2]. The Lancet Oncology, 20, 663-673.
[22] Kim, T.W., Chang, H.M., Kang, H.J., et al. (2003) Phase II Study of Capecitabine plus Cisplatin as First-Line Chemotherapy in Advanced Biliary Cancer. Annals of Oncology, 14, 1115-1120. [Google Scholar] [CrossRef] [PubMed]
[23] Hong, Y.S., Lee, J., Lee, S.C., Hwang, I.G., Choi, S.H., Heo, J.S., Park, J.O., Park, Y.S., Lim, H.Y. and Kang, W.K. (2007) Phase II Study of Capecitabine and Cisplatin in Previously Untreated Advanced Biliary Tract Cancer. Cancer Chemotherapy and Pharmacology, 8, 321-328. [Google Scholar] [CrossRef] [PubMed]
[24] Valle, J., Wasan, H., Palmer, D.H., et al. (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. The New England Journal of Medicine, 362, 1273-1281. [Google Scholar] [CrossRef
[25] Shroff, R.T., Javle, M.M., Xiao, L., et al. (2019) Gemcitabine, Cisplatin, and Nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncology, 5, 824-830. [Google Scholar] [CrossRef] [PubMed]
[26] Lamarca, A., Palmer, D.H., Wasan, H.S., et al. (2021) Second-Line FOLFOX Chemotherapy versus Active Symptom Control for Advanced Biliary Tract Cancer (ABC-06): A Phase 3, Open-Label, Randomised, Controlled Trial. The Lancet Oncology, 22, 690-701. [Google Scholar] [CrossRef
[27] Mason, M.C., Massarweh, N.N., Tzeng, C.D., et al. (2021) Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Annals of Surgical Oncology, 28, 6725-6735. [Google Scholar] [CrossRef] [PubMed]
[28] Choi, W.J., Ivanics, T., Claasen, M., et al. (2022) Is It Safe to Administer Neoadjuvant Chemotherapy to Patients Undergoing Hepatectomy for Intrahepatic Cholangiocarcinoma? ACS-NSQIP Propensity-Matched Analysis. HPB (Oxford), 24, 1535-1542. [Google Scholar] [CrossRef] [PubMed]
[29] Buettner, S., Koerkamp, B.G., Ejaz, A., et al. (2017) The Effect of Preoperative Chemotherapy Treatment in Surgically Treated Intrahepatic Cholangiocarcinoma Patients—A Multi-Institutional Analysis. Journal of Surgical Oncology, 115, 312-318. [Google Scholar] [CrossRef] [PubMed]
[30] Sutton, T.L., Billingsley, K.G., Walker, B.S., et al. (2021) Neoadjuvant Chemotherapy Is Associated with Improved Survival in Patients Undergoing Hepatic Resection for Intrahepatic Cholangiocarcinoma. The American Journal of Surgery, 221, 1182-1187. [Google Scholar] [CrossRef] [PubMed]
[31] Chen, J.S., Hsu, C., Chiang, N.J., et al. (2015) A KRAS Mutation Statusstratified Randomized Phase II Trial of Gemcitabine and Oxaliplatin Alone or in Combination with Cetuximab in Advanced Biliary Tract Cancer. Annals of Oncology, 26, 943-994. [Google Scholar] [CrossRef] [PubMed]
[32] Valle, J.W., Wasan, H., Lopes, A., et al. (2015) Cediranib or Placebo in Combination with Cisplatin and Gemcitabine Chemotherapy for Patients with Advanced Biliary Tract Cancer (ABC-03): A Randomised Phase 2 Trial. The Lancet Oncology, 16, 967-978. [Google Scholar] [CrossRef
[33] Demols, A., Borbath, I., Van Den Eynde, M., et al. (2020) Regorafenib after Failure of Gemcitabine and Platinum-Based Chemotherapy for Locally Advanced/Metastatic Biliary Tumors: REACHIN, a Randomized, Double-Blind, Phase II Trial. Annals of Oncology, 31, 1169-1177. [Google Scholar] [CrossRef] [PubMed]
[34] Lamarca, A., Edeline, J. and Goyal, L. (2022) How I Treat Biliary Tract Cancer. ESMO Open, 7, Article ID: 100378. [Google Scholar] [CrossRef] [PubMed]
[35] Jaidee, R., Kukongviriyapan, V., Senggunprai, L., et al. (2022) Inhibition of FGFR2 Enhances Chemosensitivity to Gemcitabine in Cholangiocarcinoma through the AKT/MTOR and EMT Signaling Pathways. Life Sciences, 296, Article ID: 120427. [Google Scholar] [CrossRef] [PubMed]
[36] Abou-Alfa, G.K., Sahai, V., Hollebecque, A., et al. (2020) Pemigatinib for Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma: A Multicentre, Open-Label, Phase 2 Study. The Lancet Oncology, 21, 671-684. [Google Scholar] [CrossRef
[37] Goyal, L., Meric-Bernstam, F., Hollebecque, A., et al. (2023) Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. The New England Journal of Medicine, 388, 228-239. [Google Scholar] [CrossRef
[38] Abou-Alfa, G.K., Macarulla, T., Javle, M.M., et al. (2020) Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study [Published Correction Appears in Lancet Oncol. 2020 Oct; 21(10): E462]. The Lancet Oncology, 21, 796-807. [Google Scholar] [CrossRef
[39] Lamberti, D., Cristinziano, G., Porru, M., et al. (2019) HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma [Published Correction Appears in Hepatology. 2019 Feb; 69(2): 925]. Hepatology, 69, 131-142. [Google Scholar] [CrossRef] [PubMed]
[40] Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., et al. (2015) Genomic Spectra of Biliary Tract Cancer. Nature Genetics, 47, 1003-1010. [Google Scholar] [CrossRef] [PubMed]
[41] Lu, J.C., Zeng, H.Y., Sun, Q.M., et al. (2019) Distinct PD-L1/PD-1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics, 9, 4678-4687. [Google Scholar] [CrossRef] [PubMed]
[42] Kim, R.D., Chung, V., Alese, O.B., et al. (2020) A Phase 2 Mul-ti-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract Cancer. JAMA Oncology, 6, 888-894. [Google Scholar] [CrossRef] [PubMed]
[43] Oh, D.Y., Chen, L.T., He, A.R., et al. (2019) A Phase III, Randomized, Double-Blind, Placebo-Controlled, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin for Patients with Advanced Biliary Tract Cancers: TOPAZ-1. Annals of Oncology, 30, V319. [Google Scholar] [CrossRef
[44] Oh, D.Y., Lee, K.H., Lee, D.W., et al. (2022) Gemcitabine and Cisplatin plus Durvalumab with or without Tremelimumab in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open Label, Single Centre, Phase 2 Study. The Lancet Gastroenterology and Hepatology, 7, 522-532. [Google Scholar] [CrossRef
[45] Oh, D.-Y., et al. (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence, 1, 1-11. [Google Scholar] [CrossRef
[46] Shi, G.M., Huang, X.Y., Wu, D., et al. (2023) Toripalimab Com-bined with Lenvatinib and GEMOX Is Apromising Regimen as First-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma: A Single-Center, Single-Arm, Phase 2 Study. Signal Transduction and Targeted Therapy, 8, Ar-ticle No. 106. [Google Scholar] [CrossRef] [PubMed]
[47] Lin, Y., Peng, L., Dong, L., et al. (2022) Geospa-tial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 12, 2350-2371. [Google Scholar] [CrossRef
[48] Wang, N., Huang, A., Kuang, B., et al. (2022) Progress in Radiotherapy for Cholangiocarcinoma. Frontiers in Oncology, 12, Article ID: 868034. [Google Scholar] [CrossRef] [PubMed]
[49] Herrera, F.G., Bourhis, J. and Coukos, G. (2017) Radiotherapy Combination Opportunities Leveraging Immunity for the Next Oncology Practice. CA: A Cancer Journal for Clinicians, 67, 65-85. [Google Scholar] [CrossRef] [PubMed]
[50] Chen, Y.X., Zeng, Z.C., Tang, Z.Y., et al. (2010) Determining the Role of External Beam Radiotherapy in Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Analysis of 84 Patients. BMC Cancer, 10, Article No. 492. [Google Scholar] [CrossRef] [PubMed]
[51] Sandler, K.A., Veruttipong, D., Agopian, V.G., et al. (2016) Ste-reotactic Body Radiotherapy (SBRT) for Locally Advanced Extrahepatic and Intrahepatic Cholangiocarcinoma. Advances in Radiation Oncology, 1, 237-243. [Google Scholar] [CrossRef] [PubMed]
[52] Gkika, E., Hallauer, L., Kirste, S., et al. (2017) Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Intrahepatic and Extrahepatic Cholangiocarcinoma. BMC Cancer, 17, Article No. 781. [Google Scholar] [CrossRef] [PubMed]
[53] Yu, Q., Liu, C., Pillai, A., et al. (2021) Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis. Liver Cancer, 10, 433-450. [Google Scholar] [CrossRef] [PubMed]
[54] Hong, T.S., Wo, J.Y., Yeap, B.Y., et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients with Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 34, 460-468. [Google Scholar] [CrossRef
[55] Sumiyoshi, T., Shima, Y., Okabayashi, T., et al. (2018) Chemoradio-Therapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. World Journal of Surgery, 42, 2910-2918. [Google Scholar] [CrossRef] [PubMed]
[56] Chen, C., Liu, Y. and Cui, B. (2021) Effect of Radi-otherapy on T Cell and PD-1/PD-L1 Blocking Therapy in Tumor Microenvironment. Human Vaccines & Immunotherapeutics, 17, 1555-1567. [Google Scholar] [CrossRef] [PubMed]
[57] Liu, X., Yao, J., Song, L., et al. (2019) Local and Abscopal Responses in Advanced Intrahepatic Cholangiocarcinoma with Low TMB, MSS, PMMR and Negative PD-L1 Expres-sion Following Combined Therapy of SBRT with PD-1 Blockade. The Journal for ImmunoTherapy of Cancer, 7, Arti-cle No. 204. [Google Scholar] [CrossRef] [PubMed]
[58] Liu, Z.L., Liu, X., Peng, H., et al. (2020) Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocar-Cinoma: A Case Report. Frontiers in Medicine (Lausanne), 7, Article No. 368. [Google Scholar] [CrossRef] [PubMed]
[59] Massani, M., Bonariol, L. and Stecca, T. (2021) Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholan-Giocarcinoma, a Comprehensive Review. Journal of Clinical Medicine, 10, Article No. 2552. [Google Scholar] [CrossRef] [PubMed]
[60] Cercek, A., Boerner, T., Tan, B.R., et al. (2020) Assessment of Hepatic Arterial Infusion of Flouridine in Combination with Systemic Gemcitabine and Oxaliplatin in Patients with Un-Resectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology, 6, 60-67. [Google Scholar] [CrossRef] [PubMed]
[61] Zhou, T.Y., Zhou, G.H., Zhang, Y.L., et al. (2020) Drug-Eluting Beads Transarterial Chemoembolization with CalliSpheres Microspheres for Treatment of Unresectable Intrahepatic Cholan-Giocarcinoma. Journal of Cancer, 11, 4534-4541. [Google Scholar] [CrossRef] [PubMed]
[62] Rayar, M., Sulpice, L., Edeline, J., et al. (2015) Intra-Arterial Yttrium-90 Radioembolization Combined with Systemic Chemotherapy Is a Promising Method for Downstaging Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment. Annals of Surgical Oncology, 22, 3102-3108. [Google Scholar] [CrossRef] [PubMed]
[63] Edeline, J., Touchefeu, Y., Guiu, B., et al. (2020) Radioembolization plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology, 6, 51-59. [Google Scholar] [CrossRef] [PubMed]
[64] Rustagi, T. and Jamidar, P.A. (2014) Intraductal Radiofrequency Ablation for Management of Malignant Biliary Obstruction. Digestive Diseases and Sciences, 59, 2635-2641. [Google Scholar] [CrossRef] [PubMed]
[65] Figueroa-Barojas, P., Bakhru, M.R., Habib, N.A., et al. (2013) Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Panereatie Cancer: A Novel Palliation Technique. Journal of Oncology, 2013, Article ID: 910897. [Google Scholar] [CrossRef] [PubMed]
[66] Wu, L., Tsilimigras, D.I., Farooq, A., et al. (2019) Potential Survival Benefit of Radiofrequency Ablation for Small Solitary Intrahepatic Cholangiocarcinoma in Nonsurgically Managed Patients: A Population-Based Analysis. Journal of Surgical Oncology, 120, 1358-1364. [Google Scholar] [CrossRef] [PubMed]
[67] Mizandari, M., Kumar, J., Pai, M., et al. (2018) Interventional Radiofre-quency Ablation: A Promising Therapeutic Modality in the Management of Malignant Biliary and Pancreatic Duct Ob-struction. Journal of Cancer, 9, 629-637. [Google Scholar] [CrossRef] [PubMed]
[68] Wu, T.T., Li, W.M., Li, H.C., et al. (2017) Percutaneous Intraductal Ra-diofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life. CardioVascular and Interventional Radiology, 40, 260-269. [Google Scholar] [CrossRef] [PubMed]
[69] Jin, Y., Zhao, Q., Fan, C., et al. (2023) Influence of Peripheral T-Cell Subsets of Radiofrequency Ablation of Tumors from Different Origins. Asian Journal of Surgery. [Google Scholar] [CrossRef] [PubMed]
[70] Job, S., Rapoud, D., Dos Santos, A., et al. (2020) Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in In-tra-Hepatic Cholangiocarcinoma. Hepatology, 72, 965-981. [Google Scholar] [CrossRef] [PubMed]
[71] Chaisaingmongkol, J., Budhu, A., Dang, H., et al. (2017) Common Mo-lecular Subtypes among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell, 32, 57-70.E3. [Google Scholar] [CrossRef] [PubMed]
[72] Sia, D., Hoshida, Y., Villanueva, A., et al. (2013) Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. Gastroen-terology, 144, 829-840. [Google Scholar] [CrossRef] [PubMed]
[73] Chow, F.C. and Chok, K.S. (2019) Colorectal Liver Metastases: An Update on Multidisciplinary Approach. World Journal of Hepatology, 11, 150-172. [Google Scholar] [CrossRef] [PubMed]
[74] Charriere, B., Muscari, F., Maulat, C., et al. (2017) Outcomes of Pa-tients with Hepatocellular Carcinoma Are Determined in Multidisciplinary Team Meetings. Journal of Surgical Oncology, 115, 330-336. [Google Scholar] [CrossRef] [PubMed]